EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

“Real‐world” eligibility for anti‐amyloid treatment in a tertiary memory clinic setting

Sinthujah Vigneswaran, Everard G B Vijverberg, Frederik Barkhof, Elsmarieke van de Giessen, Afina W Lemstra, Yolande Pijnenburg, Charlotte E Teunissen, Wiesje M van der Flier, Argonde C van Harten

Alzheimer's & Dementia · 2025-06 · 21 (6)

DOI: 10.1002/alz.70375 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 12.06.2025. Verfasst von Sinthujah Vigneswaran und 8 weiteren Autor:innen. Beteiligte Einrichtung: Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, the Net…. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction, Eligibility Determination. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alzheimer's Drug Discovery Foundation, Pasman stichting, ZonMw Onderzoeksprogramma Dementie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION The societal impact of anti‐amyloid treatment (AAT) for Alzheimer's disease (AD) depends largely on patient eligibility. Estimates suggest that 1% to 18% of individuals with AD may qualify for AAT; however, data from everyday clinical practice remain limited. This study assessed AAT eligibility in patients at a tertiary memory clinic. METHODS We included 1309 new patients (63 ± 8 years, 45% women, Mini‐Mental State Examination [MMSE] 25 ± 5) who presented to the Alzheimer Center Amsterdam (2020–2022) for standardized diagnostic workup. Eligibility for AAT was based on lecanemab's approved label guidelines. RESULTS Of 1309 new patients, 514 (39% of new patients) had clinical mild cognitive impairment (MCI) or AD. Of these, 108 (8% new patients/21% clinical MCI/AD) met Clinical Dementia Rating/MMSE criteria, were amyloid positive, and had < 4 microbleeds/superficial siderosis. After further excluding apolipoprotein E ε4/ε4 homozygotes and anticoagulant users, 79 patients (6% new patients/15% clinical MCI/AD) remained eligible. DISCUSSION Findings indicate limited eligibility for AAT in tertiary memory clinics. Highlights Initial eligibility for lecanemab was 8% of all patients and 21% of those with clinical mild cognitive impairment (MCI) or Alzheimer's disease (AD) based on approved guidelines in a tertiary memory clinic population. After strict exclusions (such as apolipoprotein E ε4/ε4 homozygosity and anticoagulant use), eligibility dropped to 6% of all patients and 15% of those with clinical MCI or AD. The study highlights the limited real‐world applicability of anti‐amyloid treatment under current guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseCognitive DysfunctionEligibility DeterminationHumansFemaleMaleMiddle AgedAgedMental Status and Dementia TestsTertiary Care Centers

Stichwörter der Autor:innen

Alzheimer's diseaseanti‐amyloid treatmenteligibilityreal‐world evidence

Autor:innen und Institutionen

  • Neurochemistry Laboratory, Department of Laboratory Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands.
  • Alzheimer Center, Department of Neurology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands.
  • Amsterdam Neuroscience, Program Neurodegeneration, Amsterdam, the Netherlands.
  • Department of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.

Förderung

  • Alzheimer's Drug Discovery Foundation
  • Pasman stichting
  • ZonMw Onderzoeksprogramma Dementie
  • Dutch National Dementia Strategy
  • Health∼Holland, Topsector Life Sciences & Health
  • Edwin Bouw Fonds
  • Gieskes-Strijbisfonds
  • Stichting Dioraphte and Noaber foundation

Zitieren

APA

Vigneswaran, S., Vijverberg, E. G. B., Barkhof, F., van de Giessen, E., Lemstra, A. W., Pijnenburg, Y., Teunissen, C. E., van der Flier, W. M., & van Harten, A. C. (2025). “Real‐world” eligibility for anti‐amyloid treatment in a tertiary memory clinic setting. Alzheimer's & Dementia, 21(6). https://doi.org/10.1002/alz.70375

Vancouver

Vigneswaran S, Vijverberg EGB, Barkhof F, van de Giessen E, Lemstra AW, Pijnenburg Y, et al. “Real‐world” eligibility for anti‐amyloid treatment in a tertiary memory clinic setting. Alzheimer's & Dementia. 2025;21(6). doi:10.1002/alz.70375

BibTeX
@article{Vigneswaran2025,
  author = {Vigneswaran, Sinthujah and Vijverberg, Everard G B and Barkhof, Frederik and van de Giessen, Elsmarieke and Lemstra, Afina W and Pijnenburg, Yolande and Teunissen, Charlotte E and van der Flier, Wiesje M and van Harten, Argonde C},
  title = {“Real‐world” eligibility for anti‐amyloid treatment in a tertiary memory clinic setting},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  volume = {21},
  number = {6},
  doi = {10.1002/alz.70375}
}
Kostenlos starten →